Publications by authors named "Andrea Kay"

Claim this Profile
A
A dataset of scientific dates from archaeological sites in eastern Africa spanning 5000 BCE to 1800 CE.
Victor Iminjili, Alison Crowther, Michael T Fisher, Andrea Kay, Patrick Roberts

Sci Data· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping our reliance on the tropics can reveal the roots of the Anthropocene.
Patrick Roberts, Jed O Kaplan, David Max Findley, Rebecca Hamilton, Victor Lery Caetano-Andrade, Andrea U Kay

Nat Ecol Evol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p3k14c, a synthetic global database of archaeological radiocarbon dates.
Darcy Bird, Lux Miranda, Marc Vander Linden, Erick Robinson, R Kyle Bocinsky, Andrea Kay

Sci Data· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping past human land use using archaeological data: A new classification for global land use synthesis and data harmonization.
Kathleen D Morrison, Emily Hammer, Oliver Boles, Marco Madella, Nicola Whitehouse, Andrea Kay

PLoS One· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Archaeological assessment reveals Earth's early transformation through land use.
Lucas Stephens, Dorian Fuller, Nicole Boivin, Torben Rick, Nicolas Gauthier, Andrea Kay, M Cemre Ustunkaya

Science· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Of cattle and feasts: Multi-isotope investigation of animal husbandry and communal feasting at Neolithic Makriyalos, northern Greece.
Petra Vaiglova, Paul Halstead, Maria Pappa, Sevi Triantaphyllou, Soultana M Valamoti, Andrea Kay

PLoS One· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index, airflow obstruction and dyspnea and body mass index, airflow obstruction, dyspnea scores, age and pack years-predictive properties of new multidimensional prognostic indices of chronic obstructive pulmonary disease in primary care.
Khalid Ansari, Niall Keaney, Andrea Kay, Monica Price, Joan Munby

Ann Thorac Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, Jose M Perez-Garcia, Andrea Kay

Clin Cancer Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Eric Angevin, Jose A Lopez-Martin, Chia-Chi Lin, Jürgen E Gschwend, Andrea Harzstark, Andrea Kay

Clin Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.
Xiaofeng Wang, Andrea Kay, Oezlem Anak, Eric Angevin, Bernard Escudier

J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision in Diagnosing and Classifying COPD: Comparison of Historical Height with Current Height and Arm Span to Predict FEV(1).
Khalid Ansari, Niall Keaney, Monica Price, Joan Munby, Andrea Kay

Open Respir Med J· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
Jennifer L Beaumont, Zeeshan Butt, Jeanfrancois Baladi, Robert J Motzer, Tomas Haas, Andrea Kay

Oncologist· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Robert J Motzer, Bernard Escudier, Stephane Oudard, Thomas E Hutson, Camillo Porta, Andrea Kay

Cancer· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
Dorothy A White, Philippe Camus, Masahiro Endo, Bernard Escudier, Emiliano Calvo, Andrea Kay

Am J Respir Crit Care Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
David Lebwohl, Andrea Kay, William Berg, Jean Francois Baladi, Ji Zheng

Cancer J· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
Ruirong Yuan, Andrea Kay, William J Berg, David Lebwohl

J Hematol Oncol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines and the diagnosis of COPD.
Niall Keaney, Andrea Kay, Ian Taylor

Am J Respir Crit Care Med· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson, Camillo Porta, Andrea Kay

Lancet· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
Anne L Thomas, Bruno Morgan, Mark A Horsfield, Anthony Higginson, Andrea Kay

J Clin Oncol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
David Cella, Roy S Herbst, Thomas J Lynch, Diane Prager, Chandra P Belani, Andrea C Kay

J Clin Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Mark G Kris, Ronald B Natale, Roy S Herbst, Thomas J Lynch, Diane Prager, Andrea C Kay

JAMA· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis